Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY24 results · Jan–Mar 2024
Lincoln Pharmaceuticals reported revenue from operations of ₹142.49 crore (up 26.7% from Q4 FY23) and net profit of ₹18.60 crore (up 48.0% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 142.49 | 112.46 | +26.7% | 146.45 | −2.7% |
| Other income | 7.02 | 3.90 | +80.0% | 11.02 | −36.3% |
| Total income | 149.51 | 116.36 | +28.5% | 157.47 | −5.1% |
| Profit before tax | 22.22 | 16.98 | +30.9% | 37.71 | −41.1% |
| Net profit for the period | 18.60 | 12.56 | +48.0% | 28.04 | −33.7% |
| EPS, basic (₹) | 9.28 | 6.27 | +48.0% | 14.00 | −33.7% |
| Net margin (%) | 13.1 | 11.2 | 19.1 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 142.49 | 112.46 | +26.7% | 146.45 | −2.7% |
| Other income | 7.02 | 3.95 | +77.9% | 11.02 | −36.3% |
| Total income | 149.51 | 116.41 | +28.4% | 157.47 | −5.1% |
| Profit before tax | 22.22 | 16.98 | +30.8% | 37.71 | −41.1% |
| Net profit for the period | 18.60 | 12.56 | +48.0% | 28.04 | −33.7% |
| EPS, basic (₹) | 9.28 | 6.27 | +48.0% | 14.00 | −33.7% |
| Net margin (%) | 13.1 | 11.2 | 19.1 |
Consolidated
- Filed with BSE
- 18 May 2024, 12:49 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2024, 12:49 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE